Epilepsy is a common neurological disorder observed in an estimated prevalence of 1% of the world's population. The therapeutic strategy in treating epilepsy involves reducing neuronal excitability. Retigabine (RTG) has been developed as an orally active, neuronal potassium channel opener and with its low solubility and high permeability is identified as a class II drug under the Biopharmaceutics Classification System (BCS) as a water insoluble drug. Hence, enhancing the aqueous solubility is crucial for the dosage to be minimized thus enhancing both clinical (reducing side effects) and commercial aspects. We have approached this issue in terms of polymorphism, cocrystallization adducts including salts, cocrystals and eutectics of RTG.
